MicroRNAs and Alzheimer's Disease Mouse Models: Current Insights and Future Research Avenues

Axe Neurosciences, Centre de Recherche du CHUQ (CHUL), Québec, QC, Canada G1V4G2.
International Journal of Alzheimer's Disease 07/2011; 2011(5054):894938. DOI: 10.4061/2011/894938
Source: PubMed

ABSTRACT Evidence from clinical trials as well as from studies performed in animal models suggest that both amyloid and tau pathologies function in concert with other factors to cause the severe neurodegeneration and dementia in Alzheimer’s disease (AD) patients. Accumulating data in the literature suggest that microRNAs (miRNAs) could be such factors. These conserved, small nonprotein-coding RNAs are essential for neuronal function and survival and have been implicated in the regulation of key genes involved in genetic and sporadic AD. The study of miRNA changes in AD mouse models provides an appealing approach to address the cause-consequence relationship between miRNA dysfunction and AD pathology in humans. Mouse models also provide attractive tools to validate miRNA targets
in vivo
and provide unique platforms to study the role of specific miRNA-dependent gene pathways in disease. Finally, mouse models may be exploited for miRNA diagnostics in the fight against AD.

Download full-text


Available from: Charlotte Delay, Sep 27, 2015
35 Reads
  • Source
    • "There have been previous reports published in the literature, which highlighted specific miRNA profiles differentiating patients suffering from various neurodegenerative diseases and healthy individuals. But most studies were focused on the analysis of only those miRNAs, whose expression level changes had been previously identified to be linked to pathology development in the disease organ [6], [50], [51], [52] [55] [56]. With its advantage of the potential biomarker's known connection to disease withstanding, there are a couple of drawbacks to this approach. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A minimally invasive diagnostic assay for early detection of Alzheimer's disease (AD) is required to select optimal patient groups in clinical trials, monitor disease progression and response to treatment, and to better plan patient clinical care. Blood is an attractive source for biomarkers due to minimal discomfort to the patient, encouraging greater compliance in clinical trials and frequent testing. MiRNAs belong to the class of non-coding regulatory RNA molecules of ∼22 nt length and are now recognized to regulate ∼60% of all known genes through post-transcriptional gene silencing (RNAi). They have potential as useful biomarkers for clinical use because of their stability and ease of detection in many tissues, especially blood. Circulating profiles of miRNAs have been shown to discriminate different tumor types, indicate staging and progression of the disease and to be useful as prognostic markers. Recently their role in neurodegenerative diseases, both as diagnostic biomarkers as well as explaining basic disease etiology has come into focus. Here we report the discovery and validation of a unique circulating 7-miRNA signature (hsa-let-7d-5p, hsa-let-7g-5p, hsa-miR-15b-5p, hsa-miR-142-3p, hsa-miR-191-5p, hsa-miR-301a-3p and hsa-miR-545-3p) in plasma, which could distinguish AD patients from normal controls (NC) with >95% accuracy (AUC of 0.953). There was a >2 fold difference for all signature miRNAs between the AD and NC samples, with p-values<0.05. Pathway analysis, taking into account enriched target mRNAs for these signature miRNAs was also carried out, suggesting that the disturbance of multiple enzymatic pathways including lipid metabolism could play a role in AD etiology.
    PLoS ONE 07/2013; 8(7):e69807. DOI:10.1371/journal.pone.0069807 · 3.23 Impact Factor
  • Source
    • "It truly seems likely that in vivo mammalian brain cells will have evolved mechanisms that differ in some important ways relative to these cultured cells. Some in vivo systems have been developed already (Delay and Hebert, 2011). However, we anticipate future technically improved and validated in vivo experimental systems for mechanistic manipulations of miRNAs and the miRNA-processing machinery. "
    Experimental Neurology 12/2011; 235(2):397-401. DOI:10.1016/j.expneurol.2011.12.004 · 4.70 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNAs in blood samples have been identified as an important class of biomarkers, which can reflect physiological changes from cancer to brain dysfunction. In this report we identify concordant increases in levels of expression of miR-34a in brain and two components of mouse blood samples, peripheral blood mononuclear cells (PBMCs) and plasma, from 2 day old neonates through young adulthood and mid-life to old age at 25 months. Levels of this microRNA's prime target, silent information regulator 1 (SIRT1), in brain and the two blood-derived specimens decrease with age inversely to miR-34a, starting as early as 4 months old, when appreciable tissue aging has not yet begun. Our results suggest that: 1. Increased miR-34a and the reciprocal decrease of its target, SIRT1, in blood specimens are the accessible biomarkers for age-dependent changes in brain; and 2. these changes are predictors of impending decline in brain function, as early as in young adult mice.
    Aging 10/2011; 3(10):985-1002. · 6.43 Impact Factor
Show more